Interviews

California's Stop Dangerous Pharmacies Act aims to improve patient safety by establishing new pharmacy staffing regulations and a medication error reporting system, arising from understaffed conditions.

Nutrition is foundational to health, but healthy eating does not look the same for everyone.

Fouad Atouf, senior vice president of global biologics at US Pharmacopeia, discusses how established quality standards, drawing from the realm of small molecule drugs and evolving to meet the complexities of biologics, play a pivotal role in fostering trust.

Fouad Atouf, senior vice president of global biologics at US Pharmacopeia, discusses the importance of robust quality standards in addressing concerns regarding biosimilar safety and efficacy.

The pharmacy director of Baptist Health South Florida details the features and successes of medication delivery services they provide.

Tune into this special episode of "Public Health Matters" to gain insights into the multifaceted role of pharmacists in public health and HIV care, while also highlighting the personal journey and passions of Alsean Bryant.

Public Health Pharmacist discussed wearable technology and AI assisted technology that was displayed at the 2024 Consumer Electronics Show

The pharmacist can assist with managing drug interactions, patient education, therapy selection, physician education, and more.

Anaïs Webster Mennuti, PharmD and Kristin Speer, PharmD, BCPS, discuss their new documentary that highlights the understaffed and overwhelmed reality of retail pharmacy.

In the Augment-101 phase 2 study, 63% of patients experienced overall response rate with revumenib.

This therapeutic could work for diseases of the B cell receptor signaling transduction pathway that do not respond well to single-agent BTK inhibitor.

Expert discusses positive, real-world findings from a claims-based study looking at this therapeutic.

Tune in to this episode of the Independent Rx Forum for a comprehensive update on legal developments and insightful discussions on class action lawsuits and regulatory guidelines from the National Community Pharmacists Association.

The biosimilars landscape is set to witness significant growth, particularly in therapeutic areas like ophthalmology and immunology, with a focus on blockbuster biologics like Humira, Stelara, and Eylea.

Public Health Pharmacist discussed a captivating exploration of global public health through the lens of a pharmacist and traveler.

Tune in to this episode of Public Health Matters for a captivating exploration of global public health through the lens of a pharmacist and traveler.

Investigators will evaluate prophylactic tocilizumab prior to treatment with teclistamab.

Douglas Warner, MD, chief medical officer at eFFECTOR, provides a comprehensive overview of zotatifin and its current status in a Phase 1/2 dose escalation and expansion study, with a focus on ER+/HER2- breast cancer.

Heather McArthur, MD, clinical director of breast oncology at UT Southwestern Medical Center, discusses the toxicities associated with antibody-drug conjugates (ADCs) used in breast cancer treatment at the 2023 San Antonio Breast Cancer Symposium.

There is progress being made regarding research on immunotherapies and the mutation, which adversely affects a higher number of patients in this population.

Christina Madison, PharmD, FCCP, AAHIVP, sat down with Noha Aboelata, MD to discuss her journey opening clinics and importance of health equity.

Troy Bremer, PhD, chief scientific officer at PreludeDx, discusses biosignature model and it's potential in predicting radiation therapy response for those with early-stage invasive breast cancer.

In a recent study, people who lived in disadvantaged or rural areas were just as likely to receive the second-generation medications as people in urban areas.

However, a survival benefit was observed with using a signaling inhibitor in general for patients with angioimmunoblastic T-cell lymphoma.

The pharmacist can help patients to manage symptoms throughout the entire treatment journey.

Expert breaks down these findings and more from the GLAMM1 study at the 2023 ASH Annual Meeting.

Median overall survival is set to be more than 2 years, which is more than double the overall survival of current frontline therapies.

He also provides insight for students training in classical hematology, oncology hematology, or oncology pharmacy.